Novel inhibitors complexed with glutamate dehydrogenase

Allosteric regulation by control of protein dynamics

Ming Li, Christopher J. Smith, Matthew T. Walker, Thomas Smith

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Mammalian glutamate dehydrogenase (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of L-glutamate to 2-oxoglutarate using NAD(P)+ as coenzyme. Unlike its counterparts from other animal kingdoms, mammalian GDH is regulated by a host of ligands. The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by GTP causes excessive secretion of insulin. Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate. This was followed by high throughput studies that identified more stable inhibitors, including hexachlorophene, GW5074, and bithionol. Shown here are the structures of GDH complexed with these three compounds. Hexachlorophene forms a ring around the internal cavity in GDH through aromatic stacking interactions between the drug and GDH as well as between the drug molecules themselves. In contrast, GW5074 and bithionol both bind as pairs of stacked compounds at hexameric 2-fold axes between the dimers of subunits. The internal core of GDH contracts when the catalytic cleft closes during enzymatic turnover. None of the drugs cause conformational changes in the contact residues, but all bind to key interfaces involved in this contraction process. Therefore, it seems likely that the drugs inhibit enzymatic turn-over by inhibiting this transition. Indeed, this expansion/contraction process may play a major role in the inter-subunit communication and allosteric regulation observed in GDH.

Original languageEnglish (US)
Pages (from-to)22988-23000
Number of pages13
JournalJournal of Biological Chemistry
Volume284
Issue number34
DOIs
StatePublished - Aug 21 2009
Externally publishedYes

Fingerprint

Allosteric Regulation
Glutamate Dehydrogenase
Proteins
Bithionol
Hexachlorophene
Hyperammonemia
Hyperinsulinism
Pharmaceutical Preparations
Deamination
Coenzymes
Polyphenols
Tea
Contracts
Guanosine Triphosphate
Drug Interactions
Dimers
NAD
Glutamic Acid
Animals
Throughput

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Novel inhibitors complexed with glutamate dehydrogenase : Allosteric regulation by control of protein dynamics. / Li, Ming; Smith, Christopher J.; Walker, Matthew T.; Smith, Thomas.

In: Journal of Biological Chemistry, Vol. 284, No. 34, 21.08.2009, p. 22988-23000.

Research output: Contribution to journalArticle

Li, Ming ; Smith, Christopher J. ; Walker, Matthew T. ; Smith, Thomas. / Novel inhibitors complexed with glutamate dehydrogenase : Allosteric regulation by control of protein dynamics. In: Journal of Biological Chemistry. 2009 ; Vol. 284, No. 34. pp. 22988-23000.
@article{889d8c4da4b245d1ae745640dbb5f551,
title = "Novel inhibitors complexed with glutamate dehydrogenase: Allosteric regulation by control of protein dynamics",
abstract = "Mammalian glutamate dehydrogenase (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of L-glutamate to 2-oxoglutarate using NAD(P)+ as coenzyme. Unlike its counterparts from other animal kingdoms, mammalian GDH is regulated by a host of ligands. The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by GTP causes excessive secretion of insulin. Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate. This was followed by high throughput studies that identified more stable inhibitors, including hexachlorophene, GW5074, and bithionol. Shown here are the structures of GDH complexed with these three compounds. Hexachlorophene forms a ring around the internal cavity in GDH through aromatic stacking interactions between the drug and GDH as well as between the drug molecules themselves. In contrast, GW5074 and bithionol both bind as pairs of stacked compounds at hexameric 2-fold axes between the dimers of subunits. The internal core of GDH contracts when the catalytic cleft closes during enzymatic turnover. None of the drugs cause conformational changes in the contact residues, but all bind to key interfaces involved in this contraction process. Therefore, it seems likely that the drugs inhibit enzymatic turn-over by inhibiting this transition. Indeed, this expansion/contraction process may play a major role in the inter-subunit communication and allosteric regulation observed in GDH.",
author = "Ming Li and Smith, {Christopher J.} and Walker, {Matthew T.} and Thomas Smith",
year = "2009",
month = "8",
day = "21",
doi = "10.1074/jbc.M109.020222",
language = "English (US)",
volume = "284",
pages = "22988--23000",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "34",

}

TY - JOUR

T1 - Novel inhibitors complexed with glutamate dehydrogenase

T2 - Allosteric regulation by control of protein dynamics

AU - Li, Ming

AU - Smith, Christopher J.

AU - Walker, Matthew T.

AU - Smith, Thomas

PY - 2009/8/21

Y1 - 2009/8/21

N2 - Mammalian glutamate dehydrogenase (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of L-glutamate to 2-oxoglutarate using NAD(P)+ as coenzyme. Unlike its counterparts from other animal kingdoms, mammalian GDH is regulated by a host of ligands. The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by GTP causes excessive secretion of insulin. Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate. This was followed by high throughput studies that identified more stable inhibitors, including hexachlorophene, GW5074, and bithionol. Shown here are the structures of GDH complexed with these three compounds. Hexachlorophene forms a ring around the internal cavity in GDH through aromatic stacking interactions between the drug and GDH as well as between the drug molecules themselves. In contrast, GW5074 and bithionol both bind as pairs of stacked compounds at hexameric 2-fold axes between the dimers of subunits. The internal core of GDH contracts when the catalytic cleft closes during enzymatic turnover. None of the drugs cause conformational changes in the contact residues, but all bind to key interfaces involved in this contraction process. Therefore, it seems likely that the drugs inhibit enzymatic turn-over by inhibiting this transition. Indeed, this expansion/contraction process may play a major role in the inter-subunit communication and allosteric regulation observed in GDH.

AB - Mammalian glutamate dehydrogenase (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of L-glutamate to 2-oxoglutarate using NAD(P)+ as coenzyme. Unlike its counterparts from other animal kingdoms, mammalian GDH is regulated by a host of ligands. The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by GTP causes excessive secretion of insulin. Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate. This was followed by high throughput studies that identified more stable inhibitors, including hexachlorophene, GW5074, and bithionol. Shown here are the structures of GDH complexed with these three compounds. Hexachlorophene forms a ring around the internal cavity in GDH through aromatic stacking interactions between the drug and GDH as well as between the drug molecules themselves. In contrast, GW5074 and bithionol both bind as pairs of stacked compounds at hexameric 2-fold axes between the dimers of subunits. The internal core of GDH contracts when the catalytic cleft closes during enzymatic turnover. None of the drugs cause conformational changes in the contact residues, but all bind to key interfaces involved in this contraction process. Therefore, it seems likely that the drugs inhibit enzymatic turn-over by inhibiting this transition. Indeed, this expansion/contraction process may play a major role in the inter-subunit communication and allosteric regulation observed in GDH.

UR - http://www.scopus.com/inward/record.url?scp=69249158109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249158109&partnerID=8YFLogxK

U2 - 10.1074/jbc.M109.020222

DO - 10.1074/jbc.M109.020222

M3 - Article

VL - 284

SP - 22988

EP - 23000

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 34

ER -